Outsourcing Outlook

Despite challenges, contract manufacturers in Europe are enjoying considerable success.

Summer deals struck by Novartis and Lilly point to an evolution in contract services.

As offshore savings decline, pharmaceutical companies still have a lot of work to do to reduce costs.

CMOs must find new business models and strategies that reflect the many dimensions of the industry's realities...

CMC service providers are doing well, but clinical and preclinical CROs are doing even better.

Summer deals struck by Novartis and Lilly point to an evolution in contract services.

Providing the right information upfront may ease new requirements to assess solvent levels.

CMC service providers are doing well, but clinical and preclinical CROs are doing even better.

Global manufacturing excellence will be a game changer for CMOs that can achieve it.

Providing the right information upfront may ease new requirements to assess solvent levels.

CMO business models are out of touch with current pharma industry realities. It's time for new thinking.

Global manufacturing excellence will be a game changer for CMOs that can achieve it.

CMO business models are out of touch with current pharma industry realities. It's time for new thinking.

The recent heparin contamination event calls for a new approach to manage a lengthening pharmaceutical supply chain.

CMOs have positive outlook for 2008 but are wary of competitive pressures.

Most CROs are entering China with expectations that a significant local market opportunity will develop as major pharmaceutical companies establish research development operations there...

Another Asian services provider demonstrates the global nature of pharmaceutical outsourcing.

CMOs have positive outlook for 2008 but are wary of competitive pressures.

Another Asian services provider demonstrates the global nature of pharmaceutical outsourcing.

As globalization of drug development and manufacturing gathered steam in the early part of this decade, many pharmaceutical companies in the newly-favoured regions of Asia, Eastern Europe and Latin America added contract services as adjuncts to their generic API and dosage form businesses. These new units, which in India are known under the unfortunate acronym of CRAMS (contract research and manufacturing services), were opportunistic responses to the growing outsourcing trends. Unfortunately, in many cases, they were not truly strategic commitments to the services business.

The traditional pharmaceutical business model is disintegrating, but the new model is not much different.

The dynamics of the R&D pipeline could undercut recent CRO and CMO successes.

Candid comments from a Big Pharma executive highlight the complexity of contract manufacturing.

Could sloppy due diligence practices hurt CMOs and their clients?

Contract manufacturers slim down to improve profitability.

FDA approvals renew the threat of competition from India and China.

An industry survey finds that pharma's outsourcing practices keep the industry from reaping the full benefits of outsourcing.

An industry survey finds that pharma's outsourcing practices keep the industry from reaping the full benefits of outsourcing.

While some companies float with the tide, others grab market share while business is good.

While some companies float with the tide, others grab market share while business is good.